Classifies xylazine as Schedule III controlled dangerous substance under certain circumstances.

This bill classifies xylazine (a sedative used in veterinary medicine) as a Schedule III controlled substance under New Jersey law, except when legally used by veterinarians. It directly affects individuals who illegally manufacture, distribute, possess, or use xylazine, including those mixing it with street drugs like opioids. The bill adds xylazine and specific chemical variants to Schedule III, subjecting violations to existing criminal penalties: third-degree crimes punishable by 3-5 years in prison and fines up to $25,000 (or $35,000 for possession). This change addresses xylazine’s increasing presence in illicit drug markets, where it enhances opioid effects but does not respond to naloxone, contributing to overdose risks.